THU455 Sclerostin Inhibitor Use In The Medical Management Of Osteogenesis Imperfecta Type III

Disclosure: M.D. Lundholm: None. A. Derkyi: None. S. Talvacchio: None. J.C. Marini: Other; Self; Ultragenyx, Amgen Inc. L.Z. Khan: None. Background: Osteogenesis imperfecta (OI) is a rare collagen-related hereditary skeletal disorder with an increased fracture risk from minimal trauma, short stature...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundholm, Michelle Diane, Derkyi, Alberta, Talvacchio, Sara, Marini, Joan Carol, Khan, Leila Zeinab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Bone And Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554595/
http://dx.doi.org/10.1210/jendso/bvad114.416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554595/
http://dx.doi.org/10.1210/jendso/bvad114.416

Ejemplares similares